Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Korsana Biosciences's enterprise value was $134.13M on Nov 11, 2026, against -$123.01M a year earlier. Over the last 5 years it ranged from -$142.38M to $458.94M, with a median of $55.59M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $134.13M | – |
| 2025 | Dec 31, 2025 | -$131.03M | -341.9% |
| 2024 | Dec 31, 2024 | $54.17M | +12.3% |
| 2023 | Dec 29, 2023 | $48.23M | -73.1% |
| 2022 | Dec 30, 2022 | $179.38M | -60.9% |
| 2021 | Dec 31, 2021 | $458.94M | -30.9% |
| 2020 | Dec 31, 2020 | $664.10M | +63.6% |
| 2019 | Dec 31, 2019 | $405.95M | – |
See a number that looks wrong?